一例因类风湿性关节炎而复杂的施尼茨勒综合征病例,该病例接受了用甲醇治疗
Kensuke Irino1, Yu Kochi2, Sakurako Imamura3
1Department of Rheumatology, Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital, Hiroshima, Japan.
Modern rheumatology case reports
|May 28, 2025
概括
施尼茨勒综合征 (SchS) 和类风湿性关节炎 (RA) 很少同时存在. 甲托雷克萨特 (MTX) 有效地治疗了一名患者的SchS和RA症状,建议MTX作为潜在的SchS治疗选择.
科学领域:
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
- 皮肤病学 皮肤病学
背景情况:
- 施尼茨勒综合征 (SchS) 是一种罕见的自身炎症性疾病,其特征是疹,单克隆性胃病,发烧和关节痛.
- 同时存在的SchS与其他自身免疫或自身炎症性疾病是不常见的.
- 类风湿性关节炎 (RA) 是一种慢性自身免疫性疾病,主要影响关节.
研究的目的:
- 报告一种由类风湿性关节炎复杂化的罕见施尼茨勒综合征病例.
- 为了评估甲醇 (MTX) 在同时治疗SchS和RA方面的疗效.
- 探索对SchS的潜在治疗策略,考虑到当前治疗方法的局限性.
主要方法:
- 一个78岁的男性患者的病例报告,有反复发烧,肌痛和疹病史.
- 基于临床标准,单克隆性免疫球蛋白G gammopathy,和皮肤活检发现的SchS的诊断.
- 根据抗循环素抗体和类风湿因子水平的升高来诊断RA.
- 开始用甲状腺素 (MTX) 治疗RA,并评估其对SchS和RA症状的影响.
主要成果:
- 这名患者被诊断为施尼茨勒综合征,随后患上了类风湿性关节炎.
- 起初用胆固醇治疗只能轻微改善症状.
- 甲托雷克萨特治疗导致了类风湿性关节炎和施尼茨勒综合征症状的显著改善.
- 患者耐受MTX很好,这表明其在治疗共存的SchS和RA方面的潜在实用性.
结论:
- 这一案例凸显了施尼茨勒综合征和类风湿性关节炎的罕见同时发生.
- 甲托雷克萨特在同时治疗这两种疾病方面表现出显著的疗效.
- 通过抑制IL-1和IL-6等炎症性细胞因子,MTX可能是施尼茨勒综合征的可行和可访问的治疗选择,特别是在IL-1抑制剂不可用或昂贵的情况下.
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
278
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
278
01:23Rheumatic Heart Disease I: Introduction
53
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
53
01:21Rheumatic Heart Disease III: Medical Management
36
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
36
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
71
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
71
01:20Rheumatic Heart Disease IV: Nursing Management
41
AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
41
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
240
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
240